Data Availability
The HVP01 dataset (https://clinicaltrials.gov/ct2/show/NCT03083158) is a clinical study conducted by University of British Columbia focused on Hepatitis B vaccine Engerix-B. This study has 16 healthy subjects from two cohorts: young adults (aged 40-60) and old adults (aged 61-80). Both RNA-seq gene expressions and flow cytometry data are available across multiple visits before and after the vaccination from the same whole blood samples. Primary outcome of this study is the antibody response to the first dose of Hepatitis B vaccine. The SDY180 dataset is downloaded from the ImmPort Shared Data portal (http://www.immport.org). This study has 18 young and healthy adult volunteers (aged 18-64) randomly assigned to three study groups (n = 6 subjects/group) receiving a single intramuscular dose of 2009-2010 seasonal influenza (Fluzone, Sanofi Pasteur, PA), pneumococcal vaccine (Pneumovax23, Merck, NJ), or placebo (saline). Blood samples were collected at multiple time visits, from 7 days before vaccination to 28 days after vaccination, for microarray, whole-blood flow cytometry, and serum analysis of neutralizing antibodies. Data preprocessing details are in Supplementary Material.
